T-cell acute lymphoblastic leukemia following therapy of rhabdomyosarcoma.
Multiple studies have documented an increased risk of secondary malignancies in patients receiving alkylating agents. Secondary leukemia following chemotherapy accounts for about 20% of all secondary neoplasms; most are acute nonlymphocytic. Secondary acute lymphoblastic leukemia has rarely been reported in either adult or childhood cancer. We report the development of acute T-cell lymphoblastic leukemia in a child following successful treatment of a paravertebral embryonal rhabdomyosarcoma (ERS). Southern blot analysis of DNA extracted from the T-cell lymphoblasts, using probes homologous to loci on the short arm of chromosome 11; P-calcitonin, P40.1 and H-ras, did not demonstrate the chromosomal loss of heterozygosity (LOH), a common feature of embryonal rhabdomyosarcoma. The data presented support the assumption that de novo leukemia emerged following treatment of the primary malignancy.
Kaplinsky
C
C
Department of Pediatric-Hematology/Oncology, Beilinson Medical Center, Petah Tikva, Israel.
Frisch
A
A
Cohen
I J
IJ
Goshen
Y
Y
Jaber
L
L
Yaniv
I
I
Stark
B
B
Tamary
H
H
Zaizov
R
R
D004273:DNA, Neoplasm / Q000032:analysis; D005260:Female; D006801:Humans; D007223:Infant; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000139:chemically induced* / Q000235:genetics; D016609:Neoplasms, Second Primary / Q000139:chemically induced* / Q000235:genetics; D012208:Rhabdomyosarcoma / Q000188:drug therapy* / Q000532:radiotherapy
D004273:DNA, Neoplasm